PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications

Morawitz, Janna; Kirchner, Julian; Lakes, Jale; Bruckmann, Nils Martin; Mamlins, Eduards; Hiester, Andreas; Aissa, Joel; Loberg, Christina; Schimmöller, Lars; Arsov, Christian; Antke, Christina; Albers, Peter; Antoch, Gerald; Sawicki, L

doi:10.1016/j.ejrad.2021.109556

Cited by 22 publications

(29 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reviewing titles and abstracts, 83 records were excluded: 70 because not in the field of interest of this review, 7 as reviews, editorials, or letters, and 6 as case reports. Fifteen articles were selected, and their fulltext version was retrieved [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. No additional studies were found screening the references of these articles.…”

Section: Resultsmentioning

confidence: 99%

“…rough the literature search using the selected bibliographic databases, 15 full-text articles (853 BRPCa patients) were selected [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. All the eligible articles were recently published; different countries were represented; most of the studies were retrospective (73%) or monocentric (87%), and there were no prospective multicentre studies.…”

Section: Characteristics Of Studies and Patients Includedmentioning

confidence: 99%

“…First of all, no significant adverse effects/side effects after the injection of 18 F-PSMA-1007 were reported in the included studies [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36].…”

Section: Main Findingsmentioning

confidence: 99%

“…Overall, a good DR of 18 F-PSMA-1007 PET/CT or PET/ MRI in BRPCa patients was described [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. e DR of 18 F-PSMA-1007 PET/CT or PET/MRI was dependent on PSA serum values: in other words, higher PSA values were associated with a higher DR, with excellent DR for PSA values >1 ng/ml [24,25,29,31,33,35].…”

Section: Main Findingsmentioning

confidence: 99%

“…Regional and distant lymph nodal metastases (even with short-axis diameter less than 1 cm), local relapse, and bone metastases were the most frequent sites of metastatic lesions detected by 18 F-PSMA-1007 PET/CT or PET/MRI [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. However, these imaging methods were also able to detect soft tissues metastases [22,25,[29][30][31]36].…”

Section: Main Findingsmentioning

confidence: 99%

See 4 more Smart Citations

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

Ferrari

Treglia

2021

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Background. Prostate-specific membrane antigen- (PSMA-) targeted agents labeled with fluorine-18 (18F) have recently become available to evaluate patients with biochemical recurrent prostate cancer (BRPCa) by using positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI). We performed a systematic review and meta-analysis about the detection rate (DR) of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa patients. Methods. A comprehensive computer literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases for studies published through 17 May 2021 was carried out using the following search algorithm: “PSMA” AND “1007”. Only studies providing data on the DR of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa were included. A random-effects model was used to calculate the pooled DR on a per scan basis. Results. Fifteen articles (853 patients) were selected and included in the systematic review, and ten were included in the quantitative analysis. Most of the studies reported a good DR of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa including also patients with low prostate-specific membrane antigen (PSA) values. The DR of 18F-PSMA-1007 PET/CT or PET/MRI was dependent on PSA serum values. The pooled DR was 81.3% (95% confidence interval: 74.6–88%) with statistical heterogeneity. A significant reporting bias (publication bias) was not detected. Conclusions. 18F-PSMA-1007 PET/CT or PET/MRI showed a good DR in BRPCa patients in line with other PSMA-targeted agents. The DR of 18F-PSMA-1007 PET/CT or PET/MRI is influenced by serum PSA values. These findings should be confirmed by prospective multicentric trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of Studies and Patients Includedmentioning

confidence: 99%

Section: Main Findingsmentioning

confidence: 99%

Section: Main Findingsmentioning

confidence: 99%

Section: Main Findingsmentioning

confidence: 99%

See 3 more Smart Citations

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

Ferrari

Treglia

2021

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

Editorial for “Added Value of [18F]PSMA‐1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management”

Moses,

Ho Shon

2024

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Impact of piflufolastat F‐18 PSMA PET imaging on clinical decision‐making in prostate cancer across disease states: A retrospective review

et al. 2023

View full text Add to dashboard Cite

Introduction Piflufolastat F‐18 (18F‐DCFPyL) prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging is approved by the US food and drug administration for initial staging of high‐risk prostate cancer, biochemical recurrence (BCR), and restaging of metastatic prostate cancer. Here, we sought to assess how its integration into clinical care may have impacted the management of patients. Methods We identified 235 consecutive patients who underwent an 18F‐DCFPyL PET scan from August 2021 to June 2022. The median prostate‐specific antigen at the time of imaging was 1.8 ng/mL (Range: 0−3740 ng/mL). Descriptive statistics were used to analyze its impact on clinical care for a subset of 157 patients with available treatment information: 22 for initial staging, 109 with BCR, and 26 patients with known metastatic disease. Results PSMA‐avid lesions were detected in 154/235 (65.5% of) patients. In patients undergoing initial staging, 18/39 (46.2% of) patients had extra‐prostatic metastatic lesions; 15/39 (38.5% of) scans were negative and 6/39 (15.4%) had equivocal results. 12/22 (54.5% of) patients had a change in their treatment plan post‐PSMA PET scan while 10/22 (45.5%) had no change in their treatment plan. In the BCR cohort, 93/150 (62.0%) had a local recurrence or metastatic lesions. Equivocal and negative scans accounted for 11/150 (7.3%) and 46/150 (30.7%) of scans, respectively. 37/109 (33.9% of) patients had a change in their treatment plan, while treatment was not altered in 72/109 (66.1% of) cases. In patients with metastatic disease, 43/46 (93.5%) had PSMA‐avid lesions identified; equivocal and negative scans accounted for 2/46 (4.3%) and 1/46 (2.2%) of scan results, respectively. 6/26 (23.1%) had their tentative treatment plan adjusted after the PSMA PET scan. No change in the treatment plan was observed in 20/26 (76.9% of) cases. Conclusion Integration of F‐18 PSMA PET imaging impacted clinical decision‐making and subsequent management across all stages of prostate cancer. It remains to be seen whether this translates into superior survival outcomes.

show abstract

PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications

Cited by 22 publications

References 35 publications

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

Editorial for “Added Value of [18F]PSMA‐1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management”

Impact of piflufolastat F‐18 PSMA PET imaging on clinical decision‐making in prostate cancer across disease states: A retrospective review

Contact Info

Product

Resources

About